PTCy联合ATG预防造血干细胞移植后移植物抗宿主病的研究进展  

Research Progress of Post-Transplant Cyclophosphamide Combined with Antithymocyte Globulin in Preventing GVHD after Hematopoietic Stem Cell Transplantation——Review

作　　者：吴梦洁 叶佩佩[2] WU Meng-Jie;YE Pei-Pei(Health Science Center,Ningbo University,Ningbo 315211,Zhejiang Province,China;Department of Hematology,The Affiliated Hospital of Health Science Center,Ningbo University,Ningbo 315100,Zhejiang Province,China)

机构地区：[1]宁波大学医学部,浙江宁波315211 [2]宁波大学附属人民医院血液内科,浙江宁波315100

出　　处：《中国实验血液学杂志》2023年第6期1899-1904,共6页Journal of Experimental Hematology

基　　金：宁波市医学重点学科建设项目资助(2022-S05);浙江省医药卫生科技计划项目(2022KY1184);宁波市科技计划项目(2022S020)。

摘　　要：移植物抗宿主病(GVHD)是异基因造血干细胞移植(allo-HSCT)后的主要并发症之一,严重影响患者预后。目前有研究使用移植后环磷酰胺(PTCy)联合抗胸腺球蛋白(ATG)这一新方案预防GVHD,表明PTCy联合ATG方案在临床应用于不同类型移植中对预防GVHD的发生可能有较好的疗效;而该方案的作用机制、对免疫重建以及对病毒激活的影响仍需进一步研究。因此,本文就PTCy联合ATG预防造血干细胞移植后GVHD的研究进展作一简要综述。Graft-versus-host disease(GVHD)is one of the major complications after allogeneic hematopoietic stem cell transplantation(allo-HSCT),which seriously affects the prognosis of patients.At present,a new regimen of posttransplantation cyclophosphamide(PTCy)combined with antithymocyte globulin(ATG)has been used to prevent GVHD,indicating that PTCy combined with ATG may have a good effect on the prevention of GVHD in different types of transplantation.However,the mechanism of this regimen,its effect on immune reconstitution and viral reactivation still needs to be further studied.Therefore,this article briefly reviews the research progress of PTCy combined with ATG in preventing GVHD after HSCT.

关 键 词：移植后环磷酰胺 抗胸腺球蛋白 造血干细胞移植 移植物抗宿主病 

分 类 号：R473[医药卫生—护理学]